NCT04952402View on ClinicalTrials.gov

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

January 10, 2023

Conditions
Covid19SARS-CoV2 Infection
Interventions
BIOLOGICAL

Study-provided Moderna mRNA-1273 COVID-19 vaccine

Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).

BIOLOGICAL

Community-provided Moderna mRNA-1273 COVID-19 Vaccine

Participants received a two-dose series.

BIOLOGICAL

Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine

Participants received a two-dose series.

Trial Locations (6)

27599

Chapel Hill CRS (Site ID: 3201), Chapel Hill

60612

Rush University CRS (Site ID: 2702), Chicago

92103

UCSD Antiviral Research Center CRS, San Diego

90035-4709

UCLA CARE Center CRS, Los Angeles

02115

Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston

98104-9929

University of Washington AIDS CRS, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH